Ayako Fuchigami

Suggest Changes
Learn More
BACKGROUND Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared(More)
  • 1